TMV-based vaccine-mediated immunotherapy combined with anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody (anti-CTLA-4 mAb) treatment effectively stimulated the immune system, enhanced the immunity of CD8+ T cells, reduced tumor metastasis and improved the survival rate [82]. This evidence concerns the gene CD8A and neoplasm.